38 studies reported dispose or outcomes of adverse reactions. Traditional Chinese medicine formulation used for the treatment of influenza, Uses and controversies of Lianhua Qingwen in relation to COVID-19, by region, "How traditional Chinese medicine TCM is used to treat Covid-19", "The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule", "Clinical applications and pharmacological research progress of Lianhua Qingwen capsules/granules", "Traditional Chinese cures battle for acceptance in COVID-19 fight", "Chinese traditional medicine for Covid-19 becomes money tree", "Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID-19 Pneumonia: A Meta-Analysis", "Doctors warn against claims that Beijing-touted health supplement distributed in Canada treats COVID-19", "The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis", "Beijing pushes traditional Chinese medicine as coronavirus treatment", "China Covid-19 tsar pushed treatments without revealing business ties", "Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial", "Prominent Chinese scientist failed to disclose company ties in COVID-19 clinical trial paper", "DOH and FDA Clarify Claims on the Approval of Potential COVID-19 Treatments and Calls for Resignation of the SoH", "Lianhua Qingwen, the FDA-approved traditional Chinese med, only treats symptoms, not COVID", "HSA Advisory on Lianhua Qingwen Products for Prevention or Treatment of COVID-19", "Fraudulent Coronavirus Disease 2019 (COVID-19) Products", "Chinese medicine Lianhua Qingwen makes its way into community for COVID-19 treatment despite Australian ban", https://en.wikipedia.org/w/index.php?title=Lianhua_Qingwen&oldid=1143380058, Short description is different from Wikidata, Articles needing expert attention from January 2023, Medicine articles needing expert attention, Articles containing simplified Chinese-language text, Articles containing traditional Chinese-language text, Articles with unsourced statements from August 2022, Creative Commons Attribution-ShareAlike License 3.0, Treatment against various respiratory diseases including, This page was last edited on 7 March 2023, at 11:01. On March 27, 2019, Yiling Pharmaceutical Co. Ltd. amended the LHQW drug manual to include adverse reactions related to its clinical application. J. Pharmacovigilance. Warning 1. Res. Vahl [Oleaceae; Forsythiae Fructus], Lonicera japonica Thunb. [Lamiaceae; Pogostemonis Botanical drug] (85g), Rheum palmatum L. [Polygonaceae; Rhei Radix et Rhizoma] (51g), Rhodiola crenulata (Hook. Notably, the stomach is full after a meal, and LHQW does not directly contact the gastric mucosa, which reduces the risk of irritation of stomach mucous membrane and thus the occurrence of side-effects. The main characteristics of the eligible studies are summarized in Supplementary Table S1, while the composition of LHQW and how LHQW were reported in the original studies presented in Supplementary Table S2. 17 (13), 6264. Based Complement. Cytokine storm is an excessive immune response of the body to external stimuli such as viruses, which will stimulate the secretion of a large number of inflammatory factors and lead to cytokine cascade reaction [4,6]. Pharmacopoeia of Peoples Republic of China. A Trial of Lopinavir-Ritonavir in Covid-19. In addition, LHQW capsules could inhibit both Victoria and Yamagata lineages of influenza B virus (IBV) with the 50 % inhibitive concentrations ranging from 0.2280.150 to 0.7540.161mg/mL [26]. This study provides a basis for establishing the clinical safety profile of LHQW. As Chinese Pharmacopoeia records, LHQW consists of 13 ingredients: Forsythia suspensa (Thunb.) Eval. LHQW has been recommended by the China International Exchange and Promotive Association for Medical and Health Care and the Chinese Research Hospital Association as comprehensive treatment for moderate or chronic COVID-19 pneumonia in conjunction with routine therapy (Jin et al., 2020). Here, we performed a meta-analysis of 217 Chinese experimental studies to evaluate the safety of LHQW. Since the outbreak of COVID-19, Lianhua Qingwen Capsules have been recommended by the official Chinese "Diagnosis and Treatment Protocol for COVID-19" and widely used in designated admission hospitals for COVID-19. Lianhua Qingwen capsule and Lianhua Qingwen granules were approved to add "functional indications" to the originally approved indications: "In the conventional treatment of novel. (2020). Materia Med. Publication bias data are shown in Table 2 and the Funnel plot of pooled studies presented in Figure 3. Though no specific drug has been developed so far, emerging agents have been confirmed effective or potentially beneficial to restrain it. Finally, 217 experimental studies on the Chinese population were included for study featuring 1759 cases of adverse reactions following clinical treatment (publication years ranging from 2005 to 2021). Finally, all adverse reactions were described solely based on grouping of patients into treatment and control categories and no data were obtained according to gender stratification, which limited further analysis. Among the 13 included studies on treatment of hand-foot-mouth disease, eight reported adverse reactions. The participants, interventions, comparison, outcome and study design (PICOS) criteria were used to identify articles: 1) participants: patients treated with LHQW, 2) interventions: LHQW or LHQW combined with conventional drug (LHQW capsule: Shijiazhuang Yiling Pharmaceutical Co., Ltd., National medicine approval Z20040063; LHQW granule: Shijiazhuang Yiling Pharmaceutical Co., Ltd., National medicine approval Z20100040), 3) comparison: conventional drugs, including antiviral drugs, conventional antibiotics or symptomatic treatment, 4) outcome: relevant data on adverse reactions, and 5) study design: experimental study. [3], Lianhua Qingwen was developed by Shijiazhuang Yiling Pharmaceutical in 2003 as a treatment for severe acute respiratory syndrome (SARS) following the outbreak of the disease in 2002 and was listed by the National Health Commission of China in 2004 as a treatment for influenza and other respiratory disease. Prof. Zhenhua Jia formulates the prescription of Lianhua Qingwen based on the theory of collateral disease, and participates in the research projects of Lianhua Qingwen against H 1 N 1 and COVID-19. LYY19H280006, No. Therefore, we conducted a systematic review of the . System-Organ Code Retrieval Involved. In the evaluation of treating disease, the incidence of adverse reactions during treatment of influenza A (H1N1) and influenza were lower in the LHQW group compared to the conventional drug group. 6 (26), 8485. doi:10.1007/s12325-020-01351-9, Kupferschmidt, K., and Cohen, J. 17 studies focused on the treatment of Influenza A (H1N1), 12 of which reported adverse reactions. 43 studies on treatment of respiratory tract infection were examined, with 29 reporting adverse reactions. Contraindications . The search keywords for screening the literature information were virus, COVID-19, or SARS-CoV-2, and Lianhua Qingwen. the Need for Accurate Scientific Nomenclature for Plants. (2021). 20 studies documented other adverse reactions. Potential publication bias was assessed using Funnel plot, Beggs and Eggers test. Before Five studies reported heart rate and arrhythmia as adverse events. For hand-foot-mouth disease, sample size (p = 0.082), year of publication (p = 0.795), and treatment of the control group (p = 0.701) did not explain the issue of heterogeneity. Literature searching and extraction of data were done by CH, BH, FG, and ML. These results were different from our findings, which may be attributed to the limited number of adverse reactions reported in the previous study. Analysis of curative effects of 51 patients with COVID-19 treated with Chinese medicine Lianhua Qingwen: a multicentre retrospective study. Due to the low quality of the clinical research, the accuracy of this conclusion needs to be conducted to verify. Otherwise, the fixed-effects model was used (DerSimonian and Laird, 1986; Higgins et al., 2003). [Lamiaceae; 1-Menthol] (7.5g), Glycyrrhiza uralensis Fisch. Identification of a pharmacological biomarker for the bioassay-based quality control of a thirteen-component TCM formula (Lianhua Qingwen) used in treating influenza A virus (H1N1) infection. Chin. Accessibility Data were considered statistically significant at p values <0.05. (2015). 13:764774. doi: 10.3389/fphar.2022.764774. Systematic review of efficacy and safety of Lianhua Qingwen capsules in treatment of viral influenza. (2020). For pooled studies, there was a significantly reduced risk of adverse reactions with LHQW group compared to the conventional drug group (RR = 0.63, 95% CI = 0.580.69, p < 0.001). The following terms were searched using the title, abstract or keywords in the English databases: Lianhuaqinwen granule, Lianhuaqinwen capsule, Lianhua Qingwen capsule/granule. For the Chinese databases, the search terms used were: , , /.. Vahl (Lianqiao); Lonicera japonica Thunb. LHQW has a reduced incidence of other adverse reactions compared to the conventional drug group (RR = 0.60, 95% CI = 0.430.84, p = 0.003). The outcome measures included the alleviation of fever and other symptoms including nasal congestion, sore throat, cough, aches and pains, fatigue, headache, chills or sweats in subjects with acute uncomplicated influenza. Traditional Chinese medicine for pulmonary fibrosis therapy: progress and future prospects. In recent years, LHQW has been registered to obtain marketing authorization in Canada, Brazil, Singapore, Thailand, the Philippines, Kuwait and other countries under the designation Chinese patent medicine, medicine, physical natural health products, food supplement, modern botanical medicine or natural medicine (Yiling Pharmaceutical, 2020). (Jinyinhua), Ephedra sinica Stapf (Mahuang), Armeniacae Amarum Semen (Kuxingren), Gypsum Fibrosuum (Shigao), Isatis tinctoria L. (Banlangen), Dryopteridis Crassirhizomatis Rhizoma (Mianmaguanzhong), Houttuynia cordata Thunb. Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease. Meta-Analysis of Efficacy of Oseltamivir and Substitution Therapy for Anti- H1n1 Infection. China Central Television News (2020). Cheng D.Z., Li Y. The LHQW group has a reduced incidence of gastrointestinal system damage than the conventional drug group (RR = 0.83, 95% CI = 0.740.93, p = 0.002). Besides, in view of the definite effects of LHQW in preventing severe viral infections such as SARS and COVID-19 [17,44,45,49,52,53], LHQW may represent a considerable and effective strategy against unknown viral epidemics. Efficacy of Lianhuaqingwen capsule compared with oseltamivir for influenza A virus infection: a meta-analysis of randomized, controlled trials. Lianhua Qingwen (LHQW) is a commonly used Chinese medical preparation to treat viral influenza, including in the fight against SARS in 20022003 in China. doi:10.1136/bmj.d5928, Higgins, J. P., Thompson, S. G., Deeks, J. J., and Altman, D. G. (2003). However, no statistical difference was detected with regard to rash (RR = 0.60, 95% CI = 0.211.67) and dizziness (RR = 1.79, 95% CI = 0.339.74). Lianhua-qingwen Displays Antiviral and Anti-inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). Besides, on April 14, 2020, the National Medical Products Administration of China approved modifying the specification of LHQW (Yiling Pharmaceutical Inc.) by adding a new indication for COVID-19 treatment in mild and normal cases. [4][7], Lianhua Qingwen should be avoided for patients with G6PD deficiency, since its active ingredient, Lonicera japonica, will lead to hemolysis to such patients. Traditional Chinese medicine has accumulated substantial clinical experience over thousands of years. Alternat Med. Currently, the drug has been approved for marketing in 23 countries and regions, including Canada, Russia, Cambodia and Indonesia. Five studies reported respiratory system damage as an adverse event. Traditional Chin. (2020). [8] A January 2022 meta-analysis from China reports that it may cause GI discomfort, rashes and itches, dry mouth, and dizziness, but emphasizes that the effects are more common with "conventional treatment". Cui L.F., Xu H.R., Li F.Z., Wang C.X. 327 (7414), 557560. There was no statistically significant difference in the incidence of adverse reactions during treatment of rheum between the LHQW group and the conventional drug group (RR = 0.46, 95% CI = 0.121.83, p = 0.270). 12 (08), 140141. Clinical efficacy and mechanism of Lianhua Qingwen Granule on COVID-19 based on network pharmacology research. Some composition of LHQW can cause damage to the stomach and intestines, supporting the possibility of injurious effects on the gastrointestinal system: for thia suspensa (Thunb.) Further long-term high-quality studies are essential to validate our conclusions. There was no statistically significant difference in the incidence of adverse reactions during treatment of respiratory tract infection between the LHQW group and the conventional drug group (RR = 0.78, 95% CI = 0.581.03, p = 0.083). Copyright 2022 Hu, He, Gong, Liang, Zhao and Zhang. Ther. Methods: Comprehensive document retrieval was performed from both English and Chinese databases. BMJ. Medicinal Plant Names Services. However, no consensus has been reached on the security of LHQW to date. The search keywords for screening the literature information were virus, COVID-19, or SARS-CoV-2, and Lianhua Qingwen. [5], Sources of its formulation reportedly consist of:[6], The medicine is both in capsule and granular form. doi:10.1590/1806-9282.66.6.771, Khan, Z., Karata, Y., and Rahman, H. (2020). (2021). Liu-Cheng Li was responsible for drafting the manuscript. These data indicate that LHQW prescription protects against the virus attack, and it has been recommended in the treatment of COVID-19 in China [47]. Chin. Upon full text filtering of the remaining 715 citations, 498 were excluded due to a number of reasons (shown in Figure 1). Statistics showed that infected patients in China who received combined treatment of Traditional Chinese Medicine and modern medicine exhibited lower fatality rate and relatively better clinical outcomes. Wang S.H., Liu J.F., Zhang Y.L., Dong Z. Subgroup, sensitivity and meta-regression analyses were conducted to determine the potential sources of heterogeneity. In our meta-analysis, information on adverse reactions was clearly reported in 12 of the 17 studies while the remaining five studies provided no specific evidence of adverse reaction specifically, and the incidence of adverse reactions was lower in LHQW group than that in the conventional drug group. Available at: http://m.news.cctv.com/2020/03/17/ARTIEYQ2aws8fPYWQxjnynzo200317.shtml?from=singlemessage (Accessed Apirl 29, 2021). To clarify the in vivo effects of LHQW, Gao and colleagues recently showed that LHQW could treat influenza A virus infection in H1N1 mouse model by improving pathologic alterations and body weight loss, and reducing virus replication, lung lesions as well as inflammation [19]. These above ingredients are decocted, distilled, filtered, refrigerated, mixed well with powdered sugar, dextrin or starch, dried and finally made into LHQW (Chinese Pharmacopoeia, 2020). Lianhua Qingwen(Forsythiae fructus 225 mg, Lonicerae japonicae flos 225 mg, Ephedrae herba (processed w/ honey) 85 mg, Armeniacae semen amarum (stir-baked) . Subgroup analysis showed the incidence of dizziness or headache was significantly reduced with LHQW group (RR = 0.54, 95% CI = 0.340.84, p = 0.006), no statistical difference was detected for drowsiness and legacy neuralgia. Bethesda, MD 20894, Web Policies The authors report no declarations of interest. doi:10.5582/ddt.2020.03008, PubMed Abstract | CrossRef Full Text | Google Scholar, Cao, B., Zhang, D., and Wang, C. (2020). Anti-viral effects of Lianhua Qingwen capsule against influenza A virus. In recent years, LHQW has played a significant role in the prevention and control of viral public health events (Yao et al., 2020), and is widely accepted as a representative antiviral Chinese medicine in China. However, in evaluation of security index, Eggers test and funnel plot analyses disclosed the existence of publication bias with regard to hepatobiliary system damage, psychiatric disorders, gastrointestinal system damage and body as a whole-general disorders. Efficacy and Safety of Lianhuaqingwen for Mild or Moderate Coronavirus Disease 2019. Res. 52 (3), 5860. Literature analysis of clinical application and adverse drug reaction/event of Lianhua Qingwen capsule. doi:10.1371/journal.pmed.100009710.1136/bmj.b2535, Peng, L. L., Li, L., Shen, L., and Li, X. X. The control and improvement of the present COVID-19 situation in China could not be separated from the extensive participation of TCM, which has been proven effective by the clinical studies in COVID-19 patients [41,44,48,49]. Chinese Pharmacopoeia (2020). The recent network pharmacology studies showed that the effects of LHQW prescription was related to virus infection, inflammation and immunity, moreover, its main active ingredients were verified by molecular docking with angiotensin-converting enzyme 2 (ACE2), one receptor of SARS-CoV-2, so as to have a therapeutic effect on COVID-19 [[27], [28], [29]]. J. Intern. LHQW had been proven to accelerate the improvement of acute exacerbation of COPD (AECOPD) patients, especially for the high-risk subgroup, due to the decreased release of inflammatory mediators including IL-8, TNF- , IL-17, and IL-23 [38]. The results remained statistically robust after different number supplement of potential studies (for hepatobiliary system damage: RR = 0.90, 95% CI = 0.60 to 1.34; for psychiatric disorders: RR = 1.00, 95% CI = 0.20 to 4.91; for gastrointestinal system damage: RR = 0.86, 95% CI = 0.76 to 0.98; for body as a whole-general disorders: RR = 0.73, 95% CI = 0.212.56). TABLE 1. LHQW also decreased the influenza viral titers in the lungs of mice, with decreased inflammatory cytokine levels in the early stages of infection [24]. The research data were obtained from the academic databases (up to August 8, 2020) including Pubmed, CNKI and Web of Science, on ethnobotany and ethno medicines. Though the quality of the included literature was mixed, the lung protection effects of LHQW was demonstrated. The Trim and Fill method was further applied to assess the impact of publication bias. Due to the inclusion of Ephedra people with high blood pressure, anxiety, history of seizures, irregular heart beats, or other heart heart conditions, should avoid taking Linhua Quingwen. Fig. Progress on the efficacy and clinical application of Lianhua Qingwen capsule (LHQW). Twelve representative compounds were further quantified as chemical markers, including amygdalin, forsythoside E, salidroside, glycyrrhizic acid, chlorogenic acid, hyperin, rutin, forsythoside A, cryptochlorogenic acid, sweroside, phillyrin, and rhein (Jia et al., 2015). However, both groups did not differ in the rate of conversion to severe cases or viral assay findings. ADVERSE REACTION Uncertainty. In addition, LHQW treatment efficiently impaired the nuclear export of the viral RNPl [24]. This review provides comprehensive evidence of LHQW as a complementary strategy for treating COVID-19. conducted another single center clinical trial which was showed that seven days after treatment with LHQW granules (6g, tid) in conjunction with conventional treatment for COVID-19 patients had a total effective rate of 92.73 % accompanied by significantly reduced major symptoms including fever, cough, fatigue and chest tightness [41]. Case reports, unrelated studies, those with duplicate data, reviews, commentaries and animal-based studies were excluded from the current meta-analysis. Measuring Inconsistency in Meta-Analyses. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Chin. 66 (6), 771777. Subgroup analysis further showed the incidence of disease recurrence was lower in the LHQW group than the conventional drug group (RR = 0.33, 95% CI = 0.170.65, p = 0.001), no statistical difference was detected for secondary infection. doi:10.1142/S0192415X20500378. Business China. It blocked the early stages (02h) of virus infection, and reduced virus-induced nuclear factor-kappa B (NF-B) activation and the gene expression of interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-, interferon-inducible protein (IP)-10, and monocyte chemoattractant protein (MCP)-1 [24]. The novel coronavirus disease 2019 (COVID-19) has become a matter of international concern as the disease is spreading exponentially. No use, distribution or reproduction is permitted which does not comply with these terms. Royal Botanic Gardens, Kew science (2021). Subgroup analysis was performed based on adverse reactions and sensitivity analysis implemented to investigate the influence of each study on the overall evaluation by excluding studies in turn. It was demonstrated that the use of LHQW also brought the incidence of gastrointestinal reactions, as well as skin and its accessories injuries, including diarrhea, abdominal distension, gastrointestinal discomfort, rash, and itching, despite the low quality of the included documents [50,51]. Literature Analysis of Clinical Application and Adverse Drug Reaction/Event of Lianhua Qingwen Capsule. Cheng D.Z., Wang W.J., Li Y., Wu X.D., Zhou B., Song Q.Y. First, the data indicated that LHQW combined with conventional therapies could markedly improve the clinical symptoms, quality of life and absorption of lung infiltration during anti-viral therapy, but the level of evidence is weak due to the included small sample trial and lacking the classification of disease severity. The sensitivity results are shown in Table 2. 12, 640782. doi:10.3389/fphar.2021.640782. 161, 105126. doi:10.1016/j.phrs.2020.105126, Yang, C., Wang, Y., He, J., Yan, W., Jiang, H., Chen, Q., et al. Chen J., Wang Y.K., Gao Y., Hu L.S., Yang J.W., Wang J.R., Sun W.J., Liang Z.Q., Cao Y.M., Cao Y.B. doi:10.1111/j.1365-2796.1990.tb00199.x, Higgins, J. P., Altman, D. G., Gtzsche, P. C., Jni, P., Moher, D., Oxman, A. D., et al. Further investigation confirmed that the combination treatment of LHQW capsules (200mg/kg/day) with oseltamivir (2mg/kg/day) markedly reduced IBV infection over the individual administration of either alone in vivo, proving that LHQW capsules could be used as an assistant drug to enhance the effect of oseltamivir against IBV infection [26]. Lianhua Qingwen (simplified Chinese: ; traditional Chinese: ; lit. 48 (3), 737762. Ma Y., Zhang Z., Wei L., He S., Deng X., Ji A., Zhou B., Jiang D., Li M., Wang Y. Efficacy and safety of Reduqing granules in the treatment of common cold with wind-heat syndrome: a randomized, double-blind, double-dummy, positive-controlled trial. There was no statistically significant difference in the incidence of adverse reactions during treatment of herpes zoster between the LHQW group and the conventional drug group (RR = 0.80, 95% CI = 0.521.23, p = 0.302). Beggs test and Eggers test detected no visible publication bias for data from pooled studies and disease evaluation. Lianhua Qingwen Capsules/granules Product Details. (Lianqiao), Lonicera japonica Thunb. In treating fine particulates PM2.5 (7.5mg/kg)-exposed model rats, LHQW significantly relieved the pathological changes of thickened alveolar septum, congestion of capillary, interstitial edema and infiltration of lymphocyte and neutrophil surrounding bronchiole [34]. Drafting of the manuscript was done by CH and BH. Common side effects are heart palpitations, nausea, and vomiting. Runfeng L., Yunlong H., Jicheng H., Weiqi P., Qinhai M., Yongxia S., Chufang L., Jin Z., Zhenhua J., Haiming J. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G.PRISMA Group (2009). The results are expected to enhance its effectiveness against viruses. The https:// ensures that you are connecting to the Jie Chen, Qin Chen and Hua-Qian Jin analyzed literatures. As adverse reactions in COVID-19 pneumonia and chronic obstructive pulmonary disease treatment were only reported for a limited number of studies, no sensitivity analysis for these diseases was conducted. Broad Anti-viral Capacities of Lian-Hua-Qing-Wen Capsule and Jin-Hua-Qing-gan Granule and Rational Use against Covid-19 Based on Literature Mining. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools. Recently, a single center retrospective study showed that LHQW granules (6g, tid) combined with conventional therapy (nutritional support therapy, symptomatic therapy, antiviral and antibiotic medication) could significantly relieve the symptoms like fever, cough, weakness and short breath in COVID-19 suspected cases with good safety [40]. There was no statistically significant difference in the incidence of adverse reactions during treatment of hand-foot-mouth disease between the LHQW group and the conventional drug group (RR = 0.53, 95% CI = 0.221.30, p = 0.165). Med. Wu et al. There was no statistically significant difference in the incidence of adverse reactions during treatment of COVID-19 pneumonia between the LHQW group and the conventional drug group (RR = 0.51, 95% CI = 0.141.82, p = 0.297). Recent data also showed that LHQW played a vigorous role in COVID-19 treatment. 14 (2), 6772. Lu Y., Yang J., Wang X., Ma Z., Li S., Liu Z., Fan X. Li Q., Yin J., Ran Q.S., Yang Q., Liu L., Zhao Z., Li Y.J., Chen Y., Sun L.D., Wang Y.J., Weng X.G., Cai W.Y., Zhu X.X. J. Med. Drugs and Clinic. What Is in a Name? Lianhua Qingwen, the traditional Chinese medicine recently approved for use in the Philippines by the country's Food and Drugs Administration (FDA), only treats symptoms of the coronavirus disease 2019 (COVID-19), and not the disease itself, a traditional Chinese medicine physician said Tuesday. Now, there are no study results posted on ClinicalTrials.gov for this study yet. Twenty-three studies on other diseases were included, with 12 reporting adverse reactions. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Vahl. Pharmacol. 28 (1), 1332. doi:10.1111/j.0006-341x.2000.00455.x, Fan, Z., Guo, G., Che, X., Yang, Y., Liu, Y., Li, L., et al. Wang, Y., Greenhalgh, T., and Wardle, J. J. Pharmacovigilance. It warned that sellers who make claims that it can prevent, protect against or treat COVID-19 may face prosecution. The term adverse reaction represents any undesired and unintended response that occurs with normal drug use (Gallelli et al., 2002). Chinese Herbal Medicine ("3 Medicines and 3 Formulations") for COVID 19: Rapid Systematic Review and MetaanalysisChinese Herbal Medicine ("3 Medicines and 3 Formulations") for COVID-19: Rapid Systematic Review and Meta-Analysis. Drug Discov. LHQW capsules not only had hemagglutination inhibition activity against B/Guangzhou/0215/2012 of influenza B virus, but also inhibited the over-expression of RANTES, IL-6, IL-8, IP-10, TNF-, MCP-1, macrophage inflammatory protein (MIP)-1, and interferon (IFN)- at the mRNA level and prevented a severe inflammatory response [26]. Lianhua Qingwen capsule/granule (LHQW) is obtained by combining Ma Xing Shigan Decoction with Yinqiao Powder and widely used in the clinical treatment of respiratory disorders (Liu et al., 2010). Besides, the effective rate of chest CT in the LHQW group was 69.39 %, which was higher than 62.84 % in abidor group [44]. Data analysis were done by CH and DZ. Lian Hua Qing Wen capsules (LHQW) is the most effective and commonly-used clinical formula in treating respiratory infection for thousands of years in China.

Stouffer's Discontinued Products, British Airways Sustainability Report 2020, Articles L